
Discover critical updates from Marvell Technology, Inc.'s 8-K filing on May 29, 2025. Stay informed on corporate changes impacting MRVL stock performance.
Discover critical updates from Marvell Technology, Inc.'s 8-K filing on May 29, 2025. Stay informed on corporate changes impacting MRVL stock performance.
AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.
Former Credit Suisse employees may receive up to $150 million for exposing tax evasion failures, impacting financial sector stocks like UBS, JPMorgan, and Goldman Sachs.
Explore Verisk Analytics, Inc.'s 8-K filing from May 7, 2025. Key insights on financial status, compliance, and reporting details for investors and analysts.
Discover Exelon Corporation's robust Q1 2025 financial performance, highlighting stable revenues, cash strength, and a solid investment outlook. A must-read for investors!
Explore AstraZeneca PLC's May 2025 Form 6-K report detailing 1.55B voting rights and regulatory compliance.
Explore Kraft Heinz Company's latest 8-K report detailing stock info, debt instruments, and regulatory compliance. Essential for investors assessing KHC's financial health.
Explore Autozi Internet Technology (Global) Ltd.'s report detailing financial amendments, convertible notes, and regulatory compliance for February 2025. Key insights included.
Explore iQIYI, Inc.'s Form 6-K for February 2025, detailing key financial updates, regulatory compliance, and a significant press release to inform investors.
Virax Biolabs Group's Form 6-K highlights its alignment with U.S. health transparency for vaccine efficacy, enhancing public health decision-making and regulatory compliance.
Explore Sempra Energy's 2024 financial analysis, highlighting revenue growth, net income trends, and regulatory impacts. Key insights from the latest SEC filing guide investor strategies.
Discover Evergy, Inc.'s Q1 2024 financial performance with revenue at $5.8B and net income at $873.5M. Analyze growth prospects and regulatory risks. BUY recommended.